Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management-Reference-Cited by-同舟云学术

Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management

Published:2020-07-15 Issue:1 Volume:93 Page:491-498
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Antony Suresh J.¹,Davis Michelle A.²,Davis Monique G.²,Almaghlouth Nouf K.³^ORCID,Guevara Roberto⁴,Omar Fahad⁵,Del Rey Fernando⁶,Hassan Ali⁶,Arian Muhammad U.⁶,Antony Nishaal¹,Prakash Bharat V.¹

Affiliation:

1. Department of Medicine Texas Tech University Health Sciences Center El Paso Texas

2. Department of Medicine Burrell College of Osteopathic Medicine Las Cruces New Mexico

3. Department of Medicine, Mountain View Regional Medical Center Burrell College of Osteopathic Medicine Las Cruces New Mexico

4. Department of Clinical Pharmacy The Hospitals of Providence Transmountain Campus El Paso Texas

5. Department of Pulmonary and Critical Care Las Palmas Del Sol Healthcare El Paso Texas

6. Department of Medicine Las Palmas Del Sol Healthcare El Paso Texas

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26288

Reference21 articles.

1. Elevated interleukin‐6 and severe COVID‐19: A meta‐analysis

2. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

3. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome

4. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia

5. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19;Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice;2024-04-19

2. A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects;Clinical and Translational Science;2023-07-18

3. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection;International Journal of Molecular Sciences;2022-11-21

4. Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy;International Journal of Molecular Sciences;2022-07-19

5. Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review;World Journal of Critical Care Medicine;2022-07-09